Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Br J Cancer
; 127(10): 1799-1807, 2022 11.
Article
in En
| MEDLINE
| ID: mdl-36050448
ABSTRACT
BACKGROUND:
Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the long-term outcomes of patients with small node-negative tumours.METHODS:
The ALTTO trial randomised 8381 patients with early HER2-positive BC treated with adjuvant chemotherapy (anthracycline/taxane- or taxane/carboplatin-based), to trastuzumab (T), lapatinib (L), their sequence (T â L) or their combination (L + T). Patients with tumours ≤3 cm and node-negative were included in this sub-analysis.RESULTS:
A total of 2821 patients were analysed (median follow-up of 7 years). The median age was 52 years, and most patients had tumours ≤2 cm (64.3%). The 7-year disease-free survival (DFS) was 88.1% (95% CI 86.7-89.3%). DFS was similar for arms T, T + L and Tâ¶L and significantly lower for arm L (stratified log-rank P = 0.031). The 7-year overall survival rate was 95.9% (95% CI [95.0-96.6%) and the 7-year time-to-distant recurrence was 93.4% (95% CI 92.3-94.4%).CONCLUSION:
With most patients treated with anthracycline-based regimens, ALTTO shows that patients with small tumours treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes, similar to those of the APT trial. TRIAL REGISTRATION Clinicaltrials.gov identifier NCT00490139.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Br J Cancer
Year:
2022
Document type:
Article
Affiliation country:
Bélgica